

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

VOLUNTARY ANNOUNCEMENT THE TOTAL NUMBER OF EYE SURGERIES FOR THE FOURTH QUARTER OF 2024 AND THE YEAR ENDED 31 DECEMBER 2024

EuroEyes International Eye Clinic Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis makes this announcement. The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of the Company wishes to announce that, according to the Company’s preliminary statistics and the information currently available to the Company, the combined total number of eye surgeries performed by the Group (the “**Eye Surgeries**”) for the period between 1 October 2024 to 31 December 2024 (the “**Fourth Quarter of 2024**”) and for the year ended 31 December 2024.

The total number of Eye Surgeries for the Fourth Quarter of 2024 was 6,553 eye surgeries, representing a decrease of approximately 10% when compared to the same period in 2023 (from 1 October 2023 to 31 December 2023: 7,286 eye surgeries). The decrease was mainly attributable to the slowdown in demand for myopia correction surgeries, including laser vision correction and ICL surgeries, and to a lesser extent in the presbyopia correction surgery market.

The total number of Eye Surgeries for the year ended 31 December 2024 was 27,045 eye surgeries, representing a decrease of 4% as compared to the same period in 2023 (for the year ended 31 December 2023: 28,294 eye surgeries). The Group’s focus on presbyopia correction surgeries, which demand is less affected by the economic down cycle, helped to mitigate headwinds from the myopia correction surgery market.

The Group is optimistic that, based on its resilient business model focusing on presbyopia correction surgeries, it will return to a growth trajectory in the near term while remaining cautious for the beginning of 2025.

The figures set out in this announcement have not been audited, and may differ from the final actual figures. Investors are reminded to exercise caution when dealing in the shares of the Company.

The Company will continue to provide quarterly updates on the total number of eye surgeries performed by the Group based on the comparative figures. This announcement is made by the order of the Board, of which the Board individually and jointly accepts responsibility for the accuracy of this announcement.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 27 January 2025

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.